Prognostic significance of serum proangiogenic molecules in patients with de novo non-hodgkin lymphomas

1Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

This study was aimed to assess the clinical significances of the serum VEGF and bFGF in Thai patients with de novo NHL. Serum VEGF and bFGF concentrations were measured from 79 adult patients with newly diagnosed stage 2-4 non-Hodgkin lymphomas by quantitative sandwich enzyme immunoassay. At the time of diagnosis, the serum VEGF concentrations from 79 patients ranged from 72.0 to 2919.4pg/mL, with a mean of 668.0pg/dL. The serum bFGF concentrations ranged from undetectable to 2919.4pg/mL, with a mean of 12.15pg/dL. Multivariate analysis identified higher than the mean of serum VEGF, B symptoms, bulky diseases, anemia, and treatment with CHOP or R-CHOP as independent variables influencing the complete remission rate. From a Cox proportional hazards model, variables independently associated with overall survival were bone marrow involvement, more extranodal involvement, poor performance status, anemia, and higher than the mean of serum bFGF. Copyright © 2012 Pairaya Rujirojindakul and Arnuparp Lekhakula.

Cite

CITATION STYLE

APA

Rujirojindakul, P., & Lekhakula, A. (2012). Prognostic significance of serum proangiogenic molecules in patients with de novo non-hodgkin lymphomas. The Scientific World Journal, 2012. https://doi.org/10.1100/2012/215231

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free